TABLE 3.
Outcomes of multivariate Cox analysis for OS, Fine and Gray's analysis for BCSM and OCSM
| OS | BCSM | OCSM | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P‐value | SHR | 95% CI | P‐value | SHR | 95% CI | P‐value | |
| Age (y) | |||||||||
| <60 | reference | — | — | reference | — | — | reference | — | — |
| 60‐65 | 1.416 | 1.322‐1.516 | *** | 1.082 | 0.989‐1.184 | *** | 2.561 | 2.283‐2.873 | *** |
| 66‐70 | 2.105 | 1.879‐2.162 | *** | 1.306 | 1.181‐1.443 | *** | 4.182 | 3.742‐4.674 | *** |
| 71‐75 | 2.900 | 2.707‐3.107 | *** | 1.545 | 1.389‐1.717 | *** | 6.727 | 6.049‐7.482 | *** |
| 76‐80 | 4.914 | 4.604‐5.245 | *** | 2.208 | 1.988‐2.453 | *** | 12.008 | 10.855‐13.284 | *** |
| 81‐85 | 8.292 | 7.878‐8.829 | *** | 2.780 | 2.493‐3.099 | *** | 22.167 | 20.112‐24.433 | *** |
| >85 | 14.169 | 13.340‐15.050 | *** | 3.852 | 3.469‐4.276 | *** | 39.263 | 35.634‐43.262 | *** |
| Grade | |||||||||
| I | reference | — | — | reference | — | — | — | — | — |
| II | 1.135 | 1.075‐1.199 | *** | 2.084 | 1.845‐2.353 | *** | — | — | — |
| III‐IV | 1.703 | 1.602‐1.809 | *** | 4.486 | 3.956‐5.087 | *** | — | — | — |
| Tumor size (cm) | |||||||||
| <1 | reference | — | — | reference | — | — | reference | — | — |
| 1‐1.9 | 1.445 | 1.355‐1.541 | *** | 1.717 | 1.516‐1.944 | *** | 1.343 | 1.247‐1.447 | *** |
| 2‐2.9 | 2.116 | 1.978‐2.263 | *** | 3.041 | 2.686‐3.445 | *** | 1.681 | 1.551‐1.822 | *** |
| ≥3 | — | — | — | — | — | — | 1.869 | 1.718‐2.034 | *** |
| 3‐3.9 | 2.820 | 2.619‐3.037 | *** | 4.589 | 4.030‐5.226 | *** | — | — | — |
| ≥4 | 3.307 | 3.069‐3.565 | *** | — | — | — | — | — | — |
| 4‐4.9 | — | — | — | 5.539 | 4.810‐6.380 | *** | — | — | — |
| ≥5 | — | — | — | 5.851 | 5.032‐6.804 | *** | — | — | — |
| Subtype | |||||||||
| HR+/HER2+ (luminal B) | reference | — | — | reference | — | — | — | — | — |
| HR−/HER2− (triple negative) | 1.859 | 1.724‐2.004 | *** | 2.460 | 2.219‐2.727 | *** | — | — | — |
| HR−/HER2+ (HER2 enriched) | 1.167 | 1.048‐1.300 | ** | 1.384 | 1.200‐1.595 | *** | — | — | — |
| HR+/HER2− (luminal A) | 1.000 | 0.934‐1.071 | 0.996 | 1.065 | 0.960‐1.181 | 0.230 | — | — | — |
| Surgery to primary sites | |||||||||
| Yes | reference | — | — | reference | — | — | reference | — | — |
| No | 3.428 | 3.227‐3.641 | *** | 4.031 | 3.687‐4.406 | *** | 2.037 | 1.851‐2.242 | *** |
| C‐index (95%CI) | 0.801 (0.795, 0.806) | 0.830 (0.824, 0.836) | 0.806 (0.798, 0.814) | ||||||
Abbreviations: BCSM, breast cancer‒specific mortality; CI, confidence interval; HER2−, human epidermal growth factor receptor type 2 negative; HER2+, human epidermal growth factor receptor type 2 positive; HR, hazard ratio; HR−, hormone receptor negative; HR+, hormone receptor positive; OCSM, other causes‐specific mortality; OS, overall survival; SHR, subdistribution hazard ratio.
**
P < .05.
***
P < .001.